BPC-157 (PL 14736)
Synthetic pentadecapeptide derived from human gastric juice protein (BPC). Under active preclinical investigation for gastrointestinal mucosal repair, tendon/ligament healing, and angiogenesis modulation. Not approved by FDA or international drug agencies.
60-Second Scientific Briefing
BPC-157 is an experimental 15-amino acid synthetic peptide derived from a human gastric juice protein fragment. Investigated in animal models for soft tissue healing, tendon repair, and cytoprotection. It is NOT FDA-approved for human treatment, is banned by WADA under Category S0, and is restricted under FDA compounding alerts.
What is BPC-157?
Pharmacological Classification & Molecular IdentitySynthetic pentadecapeptide comprising 15 amino acids derived from the sequence of human gastric body protection compound protein.
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingBiological pathway and target receptor binding mechanism.
Receptor Selectivity: Preclinical studies report upregulation of growth hormone receptor expression in tendon fibroblasts, modulation of VEGF and VEGFR2 pathways, and stimulation of NO synthesis.
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsNot approved by the US FDA for any indication. Placed in Compounding Category 2 (substances that raise significant safety risks in compounding). Prohibited by WADA under Category S0 (Non-approved substances).
BPC-157 is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesEvidence is largely restricted to in vitro and rodent in vivo models; there are no completed peer-reviewed Phase 2 or Phase 3 human randomized controlled trials confirming therapeutic efficacy.
Clinical Evidence
Evidence is largely restricted to in vitro and rodent in vivo models; there are no completed peer-reviewed Phase 2 or Phase 3 human randomized controlled trials confirming therapeutic efficacy.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesDue to the absence of systematic human clinical trials, comprehensive adverse effect incidence and long-term toxicology profiles are not medically established.
Theoretical concerns regarding systemic pro-angiogenic stimulation in the presence of occult malignancy, lack of pharmacokinetic data, and potential immunogenicity.
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNOT ESTABLISHED. No approved human dose, medical regimen, or clinical administration guideline exists.
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Synthetic pentadecapeptide comprising 15 amino acids derived from the sequence of human gastric body protection compound protein.
- Targets & Selectivity: Preclinical studies report upregulation of growth hormone receptor expression in tendon fibroblasts, modulation of VEGF and VEGFR2 pathways, and stimulation of NO synthesis.
- Evidence is largely restricted to in vitro and rodent in vivo models; there are no completed peer-reviewed Phase 2 or Phase 3 human randomized controlled trials confirming therapeutic efficacy.
- Safety considerations: Due to the absence of systematic human clinical trials, comprehensive adverse effect incidence and long-term toxicology profiles are not medically established.
? Unknown / Under Ongoing Investigation
- Theoretical concerns regarding systemic pro-angiogenic stimulation in the presence of occult malignancy, lack of pharmacokinetic data, and potential immunogenicity.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysBPC-157 is classified as a Synthetic Pentadecapeptide Modulator. Molecular structure: Synthetic pentadecapeptide comprising 15 amino acids derived from the sequence of human gastric body protection compound protein..
Pharmacological classification and molecular integrity are documented in verified regulatory and scientific literature.
- From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management (International Journal of Molecular Sciences, 2026-03-22)
BPC-157 exerts biological activity via Preclinical studies report upregulation of growth hormone receptor expression in tendon fibroblasts, modulation of VEGF and VEGFR2 pathways, and stimulation of NO synthesis..
Receptor binding affinity and selectivity dictate the physiological response observed in laboratory and clinical trials.
- From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management (International Journal of Molecular Sciences, 2026-03-22)
Regulatory status: Not approved by the US FDA for any indication. Placed in Compounding Category 2 (substances that raise significant safety risks in compounding). Prohibited by WADA under Category S0 (Non-approved substances).
Investigational and research-only compounds cannot be legally distributed or marketed as prescription drugs.
- World Anti-Doping Agency (WADA) Prohibited List: Non-Approved Substances (S0) and Peptide Hormones (S2) (World Anti-Doping Agency, 2024-01-01)
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Clinical evaluation status: Evidence is largely restricted to in vitro and rodent in vivo models; there are no completed peer-reviewed Phase 2 or Phase 3 human randomized controlled trials confirming therapeutic efficacy.
Clinical trial readouts and systematic analyses establish the boundary between demonstrated findings and experimental hypotheses.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
- From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management (International Journal of Molecular Sciences, 2026-03-22)
Reported safety profile: Due to the absence of systematic human clinical trials, comprehensive adverse effect incidence and long-term toxicology profiles are not medically established.
Adverse reaction monitoring and contraindications are critical parameters in pharmacological risk-benefit evaluation.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Key scientific uncertainties: Theoretical concerns regarding systemic pro-angiogenic stimulation in the presence of occult malignancy, lack of pharmacokinetic data, and potential immunogenicity.
Egypt Peptides enforces strict transparency regarding scientific limitations and gaps in longitudinal clinical data.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
NOT ESTABLISHED. No approved human dose, medical regimen, or clinical administration guideline exists.
Under medical governance mandates, clinical study dosages represent strictly controlled experimental parameters and must never be interpreted as individual therapeutic advice.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Storage status: NOT ESTABLISHED. Unregulated for commercial human pharmacy distribution. Research materials require laboratory handling under sterile, controlled cold-storage parameters.
Peptide integrity degrades rapidly when exposed to elevated temperatures, repeated freeze-thaw cycles, or direct UV light exposure.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Yes. Unapproved pharmacological substances are strictly prohibited at all times in competitive sports under WADA Category S0 (Non-approved substances) or Category S2.
Athletes subject to drug testing face strict liability and multi-year competition bans upon detection of prohibited peptides or their metabolites.
- World Anti-Doping Agency (WADA) Prohibited List: Non-Approved Substances (S0) and Peptide Hormones (S2) (World Anti-Doping Agency, 2024-01-01)
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Egypt Peptides provides peer-reviewed scientific reference monographs for research documentation. We strictly prohibit individual medical consultations, reconstitution guides, stacking recipes, or off-label use instructions.
All scientific claims must link to verified authoritative sources (FDA, PubMed, ClinicalTrials.gov) with zero tolerance for ungrounded marketing claims.
- From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management (International Journal of Molecular Sciences, 2026-03-22)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and peer-reviewed studiesWorld Anti-Doping Agency (WADA) Prohibited List: Non-Approved Substances (S0) and Peptide Hormones (S2) ↗
https://www.wada-ama.org/en/prohibited-list
FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) ↗
https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management ↗
https://doi.org/10.3390/ijms27062876